{"preliminary_commentary":{"by_channel":{"x_thread":4,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["cabozantinib"]],"indication":"metastatic renal cell carcinoma with brain metastases","name":"CABRAMET","nct_id":"NCT03967522","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cabramet-nct03967522. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CABRAMET","arms":[{"description":"All participants will be treated by 60 mg of cabozantinib once daily.","label":"Cabozantinib treatment","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-11-01","type":"ACTUAL"},"conditions":["Metastatic Renal Cell Carcinoma"],"enrollment":{"count":26,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Cabozantinib","otherNames":[],"type":"DRUG"}],"last_update":"2025-08-08","lead_sponsor":"Centre Leon Berard","official_title":"CABRAMET: A Phase 2 Study of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-10-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"The non progression rate in brain metastases at 6 months","timeFrame":"At 6 months for each patient"}],"references":[{"citation":"Negrier S, Mourey L, Dalban C, Gross-Goupil M, Flechon A, Escudier B, Barthelemy P, Oudard S, Colomba E, Thibault C, Ravaud A, Chevreau C, Boyle HJ, Blanc E, Chabaud S, Perol D, Albiges L, Flippot R; Groupe d'Etude des Tumeurs UroGenitale (Urogenital Tumor Study Group, GETUG) investigators. Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET. Eur J Cancer. 2026 May 15;239:116712. doi: 10.1016/j.ejca.2026.116712. Epub 2026 Apr 1.","pmid":"41946178","type":"DERIVED"}],"start_date":{"date":"2019-11-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases","url":"https://clinicaltrials.gov/study/NCT03967522"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cabramet-nct03967522"}